Stay updated on APL-2 Efficacy & Safety in PNH Patients Clinical Trial
Sign up to get notified when there's something new on the APL-2 Efficacy & Safety in PNH Patients Clinical Trial page.

Latest updates to the APL-2 Efficacy & Safety in PNH Patients Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedRevision: v3.3.4 was added and v3.3.3 was removed, reflecting a minor version update; core study details, eligibility criteria, and locations remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check16 days agoNo Change Detected
- Check31 days agoChange DetectedLocations section was updated with added sites across the US, Australia, Belgium, Canada, France, Germany, Japan and other regions, and some sites were removed. The study record revision was updated from v3.3.2 to v3.3.3.SummaryDifference2%

- Check60 days agoChange DetectedPublications are now described as automatically populated from PubMed and may not all be about the study. The page revision line shows Revision: v3.3.2.SummaryDifference0.1%

- Check67 days agoChange DetectedDeleted the government funding status notice from the page, and core study details such as design, endpoints, and eligibility remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check81 days agoChange DetectedNo significant changes detected on the Study Details page for NCT03500549. Core information such as the study title, conditions, interventions, eligibility criteria, and locations appears unchanged.SummaryDifference0.3%

- Check110 days agoChange Detected- Updated operating-status notice and new version tag (v3.2.0) added; old version tag (v3.1.0) removed. The page now provides current status guidance and a newer software/document version.SummaryDifference2%

Stay in the know with updates to APL-2 Efficacy & Safety in PNH Patients Clinical Trial
Enter your email address, and we'll notify you when there's something new on the APL-2 Efficacy & Safety in PNH Patients Clinical Trial page.